Editas Medicine Inc (EDIT)
5.625
-0.26
(-4.50%)
USD |
NASDAQ |
May 17, 16:00
5.625
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Cash and Short Term Investments (Annual): 323.11M for Dec. 31, 2023
Cash and Short Term Investments (Annual) Chart
Historical Cash and Short Term Investments (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 323.11M |
| December 31, 2022 | 344.27M |
| December 31, 2021 | 499.84M |
| December 31, 2020 | 402.11M |
| December 31, 2019 | 457.14M |
| December 31, 2018 | 368.96M |
| Date | Value |
|---|---|
| December 31, 2017 | 329.14M |
| December 31, 2016 | 185.32M |
| December 31, 2015 | 143.18M |
| December 31, 2014 | 10.62M |
| December 31, 2013 | 2.012M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Annual) Range, Past 5 Years
323.11M
Minimum
2023
499.84M
Maximum
2021
405.30M
Average
402.11M
Median
2020
Cash and Short Term Investments (Annual) Benchmarks
| Vertex Pharmaceuticals Inc | 11.22B |
| Bristol-Myers Squibb Co | 12.28B |
| Regeneron Pharmaceuticals Inc | 10.84B |
| Cabaletta Bio Inc | 241.25M |
| Oragenics Inc | 3.484M |